Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Promising new therapies for Behcet's disease.

M H Houman1, K Hamzaoui

  • 1Department of Internal Medicine, La Rabta University Hospital and Behçet's Disease Unit Research 02/UR/08-15, Faculty of Medicine, 1007 Tunis, Tunisia.

European Journal of Internal Medicine
|April 19, 2006
PubMed
Summary

New Behcet's disease (BD) treatments are emerging, targeting the immune system with improved efficacy and safety. This review discusses novel immunosuppressants, biologics, and immunoablation strategies for BD management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Thrombophilia in systemic lupus erythematosus: A case-control study].

Journal de medecine vasculaire·2018
Same author

Update on Asthma Genetics: Results From Meta-Analyses of Candidate Gene Association Studies.

Current molecular medicine·2018
Same author

[Etiological profile of secondary Raynaud's phenomenon in an internal medicine department. About 121 patients].

Journal de medecine vasculaire·2018
Same author

Headache in a young woman: do not forget Susac's syndrome.

Reumatismo·2017
Same author

Granulomatosis with polyangiitis in Tunisia.

Reumatismo·2017
Same author

Intracardiac thrombus in Behçet's disease.

Reumatismo·2016

Area of Science:

  • Immunology and Rheumatology
  • Molecular Pathogenesis of Autoimmune Diseases

Background:

  • Behcet's disease (BD) is a complex systemic vasculitis with incompletely understood pathogenic mechanisms.
  • Advances in understanding the molecular basis of BD pathogenesis are driving the development of novel therapeutic strategies.

Purpose of the Study:

  • To review the new generation of potential treatments for Behcet's disease.
  • To discuss therapies targeting specific immune pathways and non-specific immune inhibition.
  • To highlight treatments with improved side effect profiles and targeted immune modulation.

Main Methods:

  • Review of current and emerging therapeutic approaches for Behcet's disease.
  • Discussion of novel immunosuppressants, biologic medications, tolerizing agents, and immunoablation techniques.

Related Experiment Videos

  • Analysis of therapies targeting specific inflammatory mechanisms (e.g., TNF-alpha inhibitors) and non-specific immune suppression.

    • Main Results:

    • Several new therapeutic modalities are available or in development for Behcet's disease.
    • These include interferons, tumor necrosis factor-alpha inhibitors, and immunoablation.
    • Emerging treatments offer potential for improved efficacy and safety profiles compared to conventional therapies.

    Conclusions:

    • Improved understanding of BD pathogenesis has led to targeted and novel treatment options.
    • Future Behcet's disease management will likely involve a diverse range of immunomodulatory and immunosuppressive therapies.
    • Ongoing research is crucial for optimizing treatment strategies and improving patient outcomes in Behcet's disease.